TMJ and Migraines: The Often-Missed Connection

What the overlap actually looks like in the data

The headline statistic is reproduced across multiple independent studies in different countries and populations. Among patients with diagnosed temporomandibular disorder, the prevalence of migraine — using formal International Headache Society criteria, not just self-reported "headache" — sits somewhere between 40 and 60 percent. This compares to a general adult prevalence of migraine that varies by country and definition but is usually quoted at around 12 to 15 percent in published epidemiology. The TMD population is therefore three to four times more likely to have migraine than the background population.

The reverse direction holds too. Among patients with chronic migraine — the more severe form of the condition involving headache on 15 or more days per month — the prevalence of clinically significant TMD is higher than in the general population, though the magnitude varies by study and by how strictly TMD is defined. The link is bidirectional: having one condition makes you more likely to have the other than chance alone would predict.

This overlap is not just statistical noise. It is mechanistically grounded in the way the trigeminal system processes pain, and it has clinical implications that should change the conversation in both directions — neurology and dentistry — when a patient with both conditions arrives.

The trigeminal mechanism — why these two conditions overlap

The trigeminal nerve is the largest of the cranial nerves and carries sensory information from most of the face, the jaw, the teeth, the temporomandibular joint, and — critically — the meningeal blood vessels and dura mater that are involved in migraine pain generation. The same nerve system handles input from the masseter muscles and from the cerebral vasculature. The same brainstem nuclei process both kinds of input. The same higher-order pathways carry both kinds of signal up to the cortex.

What this means in practice is that sustained pain input from one part of the trigeminal system can affect the processing of pain input from other parts. The published model, supported by both animal research and human imaging studies, is one of central sensitisation. Persistent nociceptive input from a chronically painful temporomandibular joint or chronically overloaded masseter muscle gradually lowers the threshold at which the central nervous system experiences pain from other trigeminal inputs — including the dural and vascular inputs that produce migraine. The brain becomes more responsive to pain stimuli generally; the migraine system, which is itself a sensitised pain system, becomes easier to trigger.

The reverse pattern operates too. Chronic migraine itself produces central sensitisation that can lower the threshold at which non-migraine pain inputs — including jaw and muscle inputs — produce conscious pain. Patients with chronic migraine often describe a generalised heightening of sensitivity to many kinds of stimuli, of which jaw symptoms are one form.

The two conditions therefore amplify each other through shared circuitry. Treatment that reduces input from either side may reduce the sensitisation of the whole system and improve both.

What "TMJ-related" headache actually feels like

Headache symptoms attributable to the temporomandibular joint and masticatory muscles tend to have specific features that distinguish them, at least partially, from primary migraine. The temporal pattern is the most useful signal. TMJ-related headache typically presents in the temporal region — the muscles of the temples — and the pre-auricular region just in front of the ear. It is often worse in the morning, consistent with overnight grinding and clenching producing accumulated muscle tension by the time the patient wakes up. It is often associated with palpable tenderness of the masseter and temporalis muscles on physical examination. It frequently responds to local interventions like warm compresses, gentle stretching, anti-inflammatory medication, and a well-fitted occlusal splint.

Migraine itself has different defining features: unilateral pulsating pain (though bilateral and non-pulsating presentations occur), photophobia and phonophobia during attacks, often nausea, often a recognisable trigger profile (stress, sleep changes, hormonal shifts, specific foods), and responsiveness to triptans and CGRP-targeted preventive medications.

In a patient with both conditions, the two headache patterns may coexist as distinct entities — true migraine attacks on some days, TMJ-related muscular headache on other days — or they may be mixed, with TMJ input contributing to the baseline sensitisation that makes the migraines more frequent. A careful headache diary that captures the character, duration, associated features, and triggers of each headache day is often the single most useful diagnostic tool for sorting out how much of which is happening.

What treating TMJ does to migraine, in the published trials

The evidence base is smaller and less consistent than the evidence for primary migraine treatment, but it is meaningfully large. Several controlled studies have examined what happens to migraine frequency and severity when patients with comorbid TMD have their TMD treated, and the broad pattern is that some patients improve substantially, some improve modestly, and some do not improve at all — with the patients most likely to benefit being those with prominent TMD symptoms that are clearly contributing to their headache picture.

The specific TMD interventions with the most consistent evidence of effect on migraine include:

Custom-fitted occlusal splints. The published trials show modest but real reductions in migraine frequency in patients with comorbid TMD who wear a properly designed splint at night. The effect size is not large, but in patients with significant nocturnal bruxism contributing to morning headache, a splint can transform the morning symptom pattern.

Physical therapy targeted at the masticatory and cervical muscles. Several trials have shown that structured physical therapy programmes addressing both TMJ and cervical contributors produce meaningful reductions in headache frequency in mixed migraine/TMD populations. The mechanism is reduction of peripheral nociceptive input from chronically tense muscles.

Botulinum toxin in the masseter region. This is an interesting case because botulinum toxin is independently FDA-approved for chronic migraine, and the standard chronic migraine injection protocol — the "PREEMPT" protocol — already includes injections into the temporalis and several muscles in the head and neck. Extending the injections to the masseter, which is not part of the standard PREEMPT protocol, has been studied in patients with comorbid TMD and shows additional benefit beyond the standard migraine sites. For the patient who has both conditions and is considering botulinum toxin treatment, the inclusion of masseter injection is worth a specific conversation with the injecting clinician.

Behavioural and cognitive interventions. Stress management, sleep hygiene, biofeedback, and cognitive-behavioural approaches have evidence of benefit for both TMD and migraine independently. For comorbid patients, these interventions affect both conditions through their shared sensitisation mechanism.